ImaginAb, which has now raised approximately $4m in total, will continue development of the imaging agent it is developing for T-cell tumours.
US-based diagnostic imaging technology developer ImaginAb completed an $8m funding round on Monday featuring Novartis Venture Fund (NVF), the corporate venturing unit formed by pharmaceutical firm Novartis.
The round was led by hedge fund sponsor Adage Capital Management with backing from venture capital firms Cycad Group and Nextech Invest, Parker Institute for Cancer Immunotherapy and individual investor Jim Pallotta.
ImaginAb was spun out of University of California, Los Angeles in 2007, and has developed technology that reengineers antibodies into smaller…
